Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$57.05 USD

57.05
3,395,231

0.00 (0.00%)

Updated May 15, 2024 04:00 PM ET

After-Market: $57.79 +0.74 (1.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook

Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.

    Lilly's Olumiant Gets Marketing Authorization in Europe

    Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.

      The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences

      The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences

        What's in Store for Avis Budget (CAR) this Earnings Season?

        Avis Budget Group Inc. (CAR) is scheduled to report fourth-quarter 2016 results after market closes on Feb 15.

          Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies

          Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies

            VASCO (VDSI) Q4 Earnings: What's in Store for the Stock?

            VASCO Data Security International Inc. (VDSI) is set to report fourth-quarter 2016 results after markets close on Feb 14.

              Should You Sell Incyte (INCY) Before Earnings?

              Incyte (INCY) looks like an exciting pick for investors as it is poised to beat at earnings season.

                Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?

                Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.

                  Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?

                  Zoetis Inc. (ZTS) is scheduled to report fourth-quarter and full year 2016 results on Feb 16 before the market opens.

                    5 Toxic Stocks to Dump or Play Short for Gains

                    Inflated price of the toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental lacuna.

                      Arpita Dutt headshot

                      5 Drug Stocks Poised to Beat Earnings Estimates in Q4

                      Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.

                        Can Prothena (PRTA) Pull a Surprise This Earnings Season?

                        Prothena Corporation plc (PRTA) is scheduled to report fourth-quarter 2016 results on Feb 14 after the market closes.

                          Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?

                          Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.

                            GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?

                            GW Pharmaceuticals plc (GWPH) is scheduled to report first-quarter fiscal 2017 results on Feb 7, before the opening bell.

                              Mallinckrodt (MNK) Earnings This Quarter: Stock to Disappoint?

                              Mallinckrodt plc (MNK) is set to report results for the quarter ended Dec. 30, 2016 on Feb 7.

                                Incyte and Calithera Enter into Deal for Oncology Candidate

                                Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.

                                  Calithera Biosciences (CALA) In Focus: Stock Jumps 46.7%

                                  Calithera Biosciences, Inc. (CALA) moved big last session, as its shares jumped almost 47% on the day.

                                    5 Toxic Stocks to Dump or Play Short Now

                                    Higher price of the toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna.

                                      Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended

                                      Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).

                                        Arpita Dutt headshot

                                        4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal

                                        Takeda to Buy ARIAD, More M&As to Follow in Biotech Sector?

                                          Incyte/Merck to Start More Epacadostat-Keytruda Studies

                                          Incyte (INCY) and Merck (MRK) announced that they have decided to initiate additional pivotal studies on epacadostat, in combination with Merck's Keytruda.

                                            Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

                                            Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

                                              Incyte Treats First Patient in Phase II GVHD Study on Jakafi

                                              Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment of GVHD.

                                                Arpita Dutt headshot

                                                Two Key FDA Decisions to Watch Out for in January 2017

                                                Incyte (INCY) and Synergy (SGYP) have important regulatory events coming up this month.

                                                  The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech

                                                  The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech